Skip to search formSkip to main contentSkip to account menu

BCX1777

Known as: BCX-1777 
National Institutes of Health

Related topics

Related topics

2 relations
forodesine hydrochloride

Broader (1)

immucillin H

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been… 
Review
2008
Review
2008
Novel purine nucleoside analogues for hematological malignancies.
Recently, the search for more effective and safer antineoplastic agents has led to synthesis and introduction into preclinical… 
Review
2006
Review
2006
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
The purine nucleoside analogs (PNA) form an important group of cytotoxic drugs active in the treatment of neoplastic and… 
2006
2006
Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T… 
2006
2006
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.
Abstract Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally… 
Highly Cited
2005
Highly Cited
2005
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme… 
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.
The profound suppression of T-cell immunity seen in patients with an inherited PNP deficiency supports the potential application… 
Highly Cited
2003
Highly Cited
2003
Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
2003
2003
Arsenate reduction in human erythrocytes and rats--testing the role of purine nucleoside phosphorylase.
Reduction of the pentavalent arsenate (AsV) to the thiol-reactive arsenite (AsIII) toxifies this environmentally prevalent form… 
Highly Cited
2001
Highly Cited
2001
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License